L-NMMA

ApprovedSmall molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

L-NMMA is one of 186 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Approved.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Breast CancerActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

SarcopeniaActive, not recruiting

GrowthActive, not recruiting

Obstructive Sleep ApneaApproved

Active, not recruiting

Pulmonary HypertensionPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 1

Active, not recruiting

SarcopeniaPhase 1

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

L-NMMA

NNational Heart, Lung, and Blood Institute (NHLBI)

Approved

2 2

Tecentriq

Roche

Preclinical

36 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Prolia

Amgen

Preclinical

14 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

DATROWAY

Daiichi Sankyo

Preclinical

4 7

Megace

Bristol-Myers Squibb

Preclinical

4 8

Blenoxane

Bristol-Myers Squibb

Preclinical

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Breast Cancer

NCT05660083

Clinical

Trials by Indication[1]

Sickle Cell Disease4 trials

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00009581·65 enrolled

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00095472·18 enrolled

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00072826·44 enrolled

Show 1 more trial

Niacin to Improve Blood Flow in People With Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00508989·30 enrolled

Breast Cancer2 trials

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Completed·TThe Methodist Hospital Research Institute·Phase 1/2·NCT02834403·37 enrolled

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT05660083·36 enrolled

MPA1 trial

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

Withdrawn·UUniversity of Wisconsin, Madison·Phase 1·NCT03066115

Endothelial Function1 trial

The Effect of Lopinavir/Ritonavir on Endothelial Function

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00076414·30 enrolled

Pulmonary Hypertension1 trial

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00327080·20 enrolled

9 more indications

Endotoxemia1 trial

Blockade of Vascular Potassium Channels During Human Endotoxemia

Completed·RRadboud University Medical Center·Phase 1·NCT00185003·36 enrolled

Pembrolizumab1 trial

Phase Ib of L-NMMA and Pembrolizumab

Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT03236935·12 enrolled

Obstructive Sleep Apnea1 trial

Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls

Completed·RRegional Hospital Holstebro·Phase 4·NCT00410085·40 enrolled

Local1 trial

Characterization of Local Vascular Effects of LNMMA

Completed·TTechnische Universität Dresden·N/A·NCT00180063

Autonomic Nervous System1 trial

Nitric Oxide and the Autonomic Nervous System

Completed·VVanderbilt University·N/A·NCT00178919·112 enrolled

Growth1 trial

Effect of DPP4 Inhibition on Growth Hormone Secretion

Completed·VVanderbilt University·Phase 4·NCT01701973·44 enrolled

Pathophysiology1 trial

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Completed·VVanderbilt University Medical Center·Phase 1·NCT01122407·34 enrolled

Sarcopenia1 trial

Insulin and Sarcopenia in the Elderly

Completed·TThe University of Texas Medical Branch, Galveston·Phase 1·NCT00690534·88 enrolled

Unspecified1 trial

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT01744236·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for L-NMMA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-NMMA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-NMMA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

L-NMMA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Sickle Cell Disease4 trials

Breast Cancer2 trials

MPA1 trial

Endothelial Function1 trial

Pulmonary Hypertension1 trial

Endotoxemia1 trial

Pembrolizumab1 trial

Obstructive Sleep Apnea1 trial

Local1 trial

Autonomic Nervous System1 trial

Growth1 trial

Pathophysiology1 trial

Sarcopenia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News